Podcasts about advances

Jennifer Aniston’s romance with hypnotist-turned-wellness expert Jim Curtis is developing much faster than fans realize, with friends saying the connection is already serious. Meanwhile, Reese Witherspoon has firmly shut down ongoing rumors that Aniston is still “pining” for Brad Pitt, calling the chatter outdated and untrue. Britney Spears say she’s terrified of ever being placed under another conservatorship, insisting she would “never allow that to happen” as concerns about her emotional stability grow again. Don't forget to vote in today's poll on Twitter at @naughtynicerob or in our Facebook group. See omnystudio.com/listener for privacy information.

Epilepsy affects up to 2% of people, and for some patients, medications are not effective. Adeel Ilyas, M.D., a neurosurgeon, explains how referral to a Level 4 epilepsy center offers hope to patients with drug-resistant epilepsy. Learn how UAB's multidisciplinary team, including neurologists, neurosurgeons, and neuropsychologists, uses both surgical and neuromodulatory approaches to manage seizures.

SPRINGFIELD — State Senator Michael E. Hastings advanced legislation designed to protect homeowners from excessive insurance rate increases and ensure fairness, transparency and accountability in Illinois homeowners insurance. "With this legislation, we are putting fairness and accountability back into the system," said Hastings (D-Frankfort). "Here is what this means for Illinois homeowners — no more surprise renewals, no more fine print, no more ‘gotcha' letters in the mail.” The legislation would establish clear rules for homeowners insurance, including: No surprise renewals: Companies would be required to give at least 60 days' notice before nonrenewal and at least 60 days' notice for premium increases over 10% or changes in coverage or deductibles. Use of Illinois-specific data: Insurers would need to use credible state-specific loss experience when setting rates. Fair, reasonable and transparent rates: Rates would need to be actuarially sound and not excessive, inadequate or unfairly discriminatory. Accountability and enforcement: The Department of Insurance would be able to review filings, issue orders and require rebates when rates are found unfair. The legislation would apply specifically to fire and extended coverage insurance for residential owner occupied properties, while excluding commercial, rental and unoccupied properties. Hastings emphasized the legislation is leveling the playing field for Illinois residents. "We are tired of the industry cherry picking data from across the country when setting their rates,” said Hastings. “This legislation guarantees homeowners a fair shake, with rates based on real Illinois data." House Bill 3799 passed the Senate on Thursday.

Living with Eosinophilic Granulomatosis with Polyangiitis (EGPA): Podcast of a Patient-Physician Discussion This podcast is published open access in Advances in Therapy and is fully citeable. You can access the original published podcast article through the Advances in Therapy website and by using this link: https://link.springer.com/article/10.1007/s12325-025-03400-7. All conflicts of interest can be found online. This podcast is intended for medical professionals. Open Access: This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit https://creativecommons.org/licenses/by-nc/4.0/.

After falling in the first round each of the last two years, Palatine got over the hump with a 29-8 win over Whitney Young on Friday.Become a supporter of this podcast: https://www.spreaker.com/podcast/friday-night-drive--3534096/support.

Today, I'm joined by Dr. Drew Taylor, a trailblazer in regenerative medicine and the innovative force behind Acorn Biolabs. Dr. Taylor's path is anything but ordinary—he went from pitching in professional baseball to pioneering non-invasive ways to collect and preserve the body's most potent cells, all sourced from our hair follicles. His journey is a testament to the power of curiosity, resilience, and the drive to use cutting-edge science for better health and longevity. ONE-FREE Year of Hair Follicle Banking: Whether it's for present use or future use, you get one full year of free banking. All you have to do is find a clinic that offers Acorn near you, sign up for your hair follicle harvest, and then go to acorn.me/nat and use code NAT at checkout to get one free year of banking. Episode Timestamps: Dr. Drew Taylor's journey: pro athlete to stem cell science ... 00:06:24 Transition from sports to regenerative medicine ... 00:09:45 Advances in stem cell therapy and cell reprogramming ... 00:11:01 Donor vs. autologous stem cell differences ... 00:12:12 Stem cell hierarchy and pluripotency explained ... 00:19:00 Limits of biological age tests ... 00:23:27 Non-invasive harvesting from hair follicles ... 00:27:36 Advantages of hair follicle cells ... 00:30:10 Age and timing for cell banking ... 00:33:02 Wound healing case study with secretome ... 00:38:19 Secretome, exosomes, and topical treatment potential ... 00:40:43 Hair regrowth and transplant support ... 00:52:12 Accessibility and affordability of Acorn's approach ... 00:56:40 Cryopreservation as a "biological insurance policy" ... 00:59:42 Microneedling and aesthetic results ... 01:00:39 Future uses: sports injuries, immune cells, organ regeneration ... 01:04:30 Final advice for longevity and health span ... 01:13:16 How to access Acorn's services ... 01:15:18 Our Amazing Sponsors: Puori - Minimally processed, made from pasture-raised cows' milk, and it's tested for over 200 contaminants every single batch. Go to Puori.com/NAT and use code NAT for 20% off— it also applies to subscriptions so you'll get nearly a third off the price. Kineon - Near-infrared light helps improve circulation, oxygen delivery, and mitochondrial function, which can support focus, recovery, and even overall brain health. Visit kineon.io/NATNIDDAM and get 10% off! Digestive Bitters by Just Thrive - One capsule before eating helps your body absorb more nutrients, ease digestion, and leave you feeling light instead of weighed down. Head over to Justthrivehealth.com/discount/NAT and use code NAT20 for 20% off. Nat's Links: YouTube Channel Join My Membership Community Sign up for My Newsletter Instagram Facebook Group

The Department of Energy's Oak Ridge National Laboratory (ORNL) has installed a Quantum Brilliance quantum computer system to advance hybrid quantum-classical computing. This collaboration aims to integrate quantum computing into classical high-performance computing (HPC) systems, enabling significant computational power gains. You can listen to all of the Quantum Minute episodes at https://QuantumMinute.com. The Quantum Minute is brought to you by Applied Quantum, a leading consultancy and solutions provider specializing in quantum computing, quantum cryptography, quantum communication, and quantum AI. Learn more at https://AppliedQuantum.com.

Send us a textInvest in pre-IPO stocks with AG Dillon & Co. Contact aaron.dillon@agdillon.com to learn more. Financial advisors only.00:00 - Intro00:08 - Mercor $350M Series C Quintuples Valuation to $10B Amid AI Data Pivot01:47 - OpenAI Restructuring to PBC Unlocks $40B Fundraising at $500B Valuation03:14 - SoftBank Greenlights $22.5B Final Tranche to OpenAI Contingent on PBC Shift04:06 - OpenAI Advances Generative Music Tool to Rival Suno in $200B Media Market05:14 - Poolside $2B Raise at $12B Valuation Backed by Nvidia's $1B Commitment05:49 - Bending Spoons $270M Raise at $11B Valuation Funds $1.4B AOL Buy06:56 - Whatnot $225M Series F at $11.5B Valuation Drives Global GMV Doubling08:08 - Figma $200M+ Weavy Acquisition Boosts AI Media Tools Post-IPO09:07 - MiniMax M2 Tops Global Open Models in Sovereign AI Push10:00 - 1X NEO Robot Preorders at $20K Target 2026 Deliveries11:10 - SpaceX $2B Pentagon Deal Bolsters $11B Starlink Revenue12:15 - Canva Debuts Foundational Design Model in Affinity Free Shift13:28 - Grammarly Rebrands to Superhuman with 40M DAU AI Suite

Women's Tennis: Japan's Sakatsume Advances to Hong Kong Open Quarterfinals

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/CPY865. CME/AAPA credit will be available until October 20, 2026.The Immunotherapy Story Continues for CSCC: Insights and Evidence on Advances in Resectable and Unresectable Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/CPY865. CME/AAPA credit will be available until October 20, 2026.The Immunotherapy Story Continues for CSCC: Insights and Evidence on Advances in Resectable and Unresectable Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/CPY865. CME/AAPA credit will be available until October 20, 2026.The Immunotherapy Story Continues for CSCC: Insights and Evidence on Advances in Resectable and Unresectable Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

Women's Soccer: Japan Advances to Quarterfinals at FIFA U-17 World Cup

Women's Tennis: Japan's Yamauchi Advances to 2nd Round at Chennai Open in India

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/CPY865. CME/AAPA credit will be available until October 20, 2026.The Immunotherapy Story Continues for CSCC: Insights and Evidence on Advances in Resectable and Unresectable Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

We recap the total domination of William Byron at Martinsville, Rowdy Dragon with your final Fantasy NASCAR Picks of the 2025 Season for Phoenix Championship Weekend, Kerry has MAJOR NEWS, Toby is heading to Phoenix, plus a full Phoenix Preview for this weekend. Hosted by Kerry Murphey and Toby Christie

In this episode of TechMagic, hosts Cathy Hackl and Lee Kebler explore the fascinating, funny, and sometimes unsettling intersection between humans and machines. From Cathy's “shopping date” with humanoid robot Maximus to Amazon's ambitious plans to automate its warehouses, the hosts unpack how AI and robotics are reshaping work and daily life. They also discuss Samsung's entry into the XR race with the Galaxy headset, the return of Bored Ape Yacht Club's metaverse project, and innovations like direct-to-vinyl recording. With equal parts humour and insight, Cathy and Lee decode how today's emerging technologies are redefining what's possible, and what's still human.Come for the tech and stay for the magic!Cathy Hackl BioCathy Hackl is a globally recognized tech & gaming executive, futurist, and speaker focused on spatial computing, virtual worlds, augmented reality, AI, strategic foresight, and gaming platforms strategy. She's one of the top tech voices on LinkedIn and is the CEO of Spatial Dynamics, a spatial computing and AI solutions company, including gaming. Cathy has worked at Amazon Web Services (AWS), Magic Leap, and HTC VIVE and has advised companies like Nike, Ralph Lauren, Walmart, Louis Vuitton, and Clinique on their emerging tech and gaming journeys. She has spoken at Harvard Business School, MIT, SXSW, Comic-Con, WEF Annual Meeting in Davos 2023, CES, MWC, Vogue's Forces of Fashion, and more. Cathy Hackl on LinkedInSpatial Dynamics on LinkedInLee Kebler BioLee has been at the forefront of blending technology and entertainment since 2003, creating advanced studios for icons like Will.i.am and producing music for Britney Spears and Big & Rich. Pioneering in VR since 2016, he has managed enterprise data at Nike, led VR broadcasting for Intel at the Japan 2020 Olympics, and driven large-scale marketing campaigns for Walmart, Levi's, and Nasdaq. A TEDx speaker on enterprise VR, Lee is currently authoring a book on generative AI and delving into splinternet theory and data privacy as new tech laws unfold across the US.Lee Kebler on LinkedInKey Discussion Topics:00:00 Intro: Welcome to Tech Magic with Cathy Hackl and Lee Kebler01:30 Shopping with Maximus: A Human-Robot Retail Adventure10:35 Amazon's Automation Revolution: 600,000 Jobs Going Robotic18:30 The AI Bubble: Debating the Reality of AGI and Market Hype28:40 Understanding ChatGPT's Limitations and Technical Challenges37:00 Samsung Galaxy XR: A New Player in the XR Hardware Space43:50 Amazon's HUD Glasses and the Future of Spatial Computing50:25 Bored Ape Yacht Club Returns with "Otherside" Metaverse Project54:58 Upcoming Events and a Deep Dive into Vintage Audio Technology Hosted on Acast. See acast.com/privacy for more information.

Health professionals and key national partners such as the National Emergency and Management Organization, Customs & Excise Department and the Saint Lucia Fire Service came together in a three-day Pandemic Preparedness and Response Plan Development Workshop from October 21st to 23rd at the Harbor Club Hotel. The workshop which was hosted by the Ministry of Health, Wellness and Elderly Affairs in collaboration with the Pan American Health Organization (PAHO) and the World Health Organization (WHO) aimed at developing a road map for coordinated national action which will ensure Saint Lucia's preparedness and response to future health emergencies. At the end of the workshop, a comprehensive plan would be created which would enhance Saint Lucia's ability to detect, respond to, and recover from pandemics, particularly those caused by respiratory diseases.

With generative AI introducing new challenges for digital security, Arun Vemury, director at the Department of Homeland Security's Science and Technology Directorate, explains how biometric technologies are enabling the agency to stay ahead of AI-driven identity fraud. The conversation explores how DHS verifies identities across complex environments — from border crossings to remote digital interactions. Vemury details the agency's collaborative approach, using cooperative research agreements and competitive evaluations to test and deploy cutting-edge biometric tools quickly. He also discusses how DHS balances strong security with seamless user experiences through multi-layered verification methods like advanced facial recognition, liveness detection and emerging video call authentication techniques.

Guest: Joel Gabre, M.D, MPH On this episode of Advances in Care, host Erin Welsh and Dr. Joel Gabre, a gastroenterologist at NewYork-Presbyterian and Columbia who specializes in cancer care, discuss the ongoing rise in colorectal cancer rates among younger individuals. Dr. Gabre lays out trends observed by the medical community in colorectal cancer rates, including the increasing likelihood by birth cohort for patients to develop this disease. He also talks about the main differences in colorectal cancer for patients from these different cohorts, most notably the location where cancers are likely to develop in the colon. In addition, Dr. Gabre shares some of the leading hypotheses for why colon cancer rates are rising in younger people, and how clinicians and researchers are focused on searching for answers to improve prevention and treatment options. He gets into the importance of the western diet in developing these forms of cancer and shares details about his team's recent findings regarding changes at the cellular level that could be contributing to the accelerated growth of these cancers. Finally, Dr. Gabre speaks to his personal experiences as a gastroenterologist who has seen first-hand the rise in colon cancer rates among his younger patients. He shares a story of what …

In this conversation, Dr. Dean Elterman, Associate Professor of Urology at the University of Toronto and a sub-specialist in functional urology, discusses benign prostatic hyperplasia (BPH), a common condition affecting men as they age. He explains the causes, symptoms, and various treatment options available, including medications, traditional surgeries, and minimally invasive procedures. The discussion also touches on the role of AI in improving treatment outcomes and the importance of lifestyle changes in managing BPH. Dr. Elterman emphasizes the need for awareness and proactive management of urinary symptoms.#prostatehealth

Andrew Gosden, a 14-year-old boy from Doncaster, England, vanished on September 14, 2007, after leaving home, withdrawing money, and purchasing a one-way train ticket to London. Despite extensive investigations, searches, and public appeals, no concrete evidence has emerged regarding his whereabouts or the reasons behind his disappearance. Multiple theories have been proposed, ranging from voluntary departure and mental health issues to abduction and foul play, but none have been confirmed. Advances in technology and renewed efforts by law enforcement continue to keep the case active, yet Andrew's fate remains unknown, leaving his family and the public with unanswered questions and a lingering hope for resolution.(commercial at 9:21)to contact me:bobbycapucci@protonmail.comBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-moscow-murders-and-more--5852883/support.

Welcome to Roll Pod, an Alabama sports podcast from Bama247. On today's episode, Mike Rodak and Alex Scarborough join Brett Greenberg to discuss Alabama's 29-22 comeback win at South Carolina as the Crimson Tide advance to 7-1 on the season heading into a bye week. FOLLOW • Brett Greenberg: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twitter.com/BrettGreenberg_⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  • Mike Rodak: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twitter.com/mikerodak⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • Alex Scarborough⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠: https://twitter.com/ByScarborough⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ LINKS • Bama247 Website: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://247sports.com/college/alabama/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  • Subscribe to Bama247: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://247sports.com/college/alabama/join/?promo=QUICKLINKS⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  • Bama247 Youtube: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.youtube.com/channel/UC2YzVw4plQnY8V8mMNCfZ8g⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  • Bama247 Twitter: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twitter.com/Bama_247⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  • Bama247 Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.instagram.com/bama_247/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  To learn more about listener data and our privacy practices visit: https://www.audacyinc.com/privacy-policy Learn more about your ad choices. Visit https://podcastchoices.com/adchoices

(0:00) The second hour begins with the guys reacting to Stephen A Smith's comments on the NBA gambling investigation. (12:32) The callers weigh in on the Bruins-Ducks game and the NBA gambling scandal. (20:21) The guys reset the Bill Belichick Hall of Fame discussion from earlier in the week. (29:34) More calls on Agenda Free Friday.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This week's developments in Israel and around the world show just how unstable and prophetic our times have become. The slow return of Israeli bodies from Gaza, the crumbling ceasefire with Hamas, the controversial annexation bill, and global shifts in power all point to the reality that prophecy is unfolding before our eyes.00:00 – Shalom from Monte Judah | This Week's Israel Prophecy UpdateMonte Judah opens with a summary of the week's major prophetic and geopolitical headlines from Israel and beyond.00:45 – 13 Israeli Bodies Returned from Gaza | Ongoing National MourningIsrael continues to recover victims from Gaza as families hold back-to-back funerals.02:00 – Hamas Breaks Ceasefire Again | Rocket and Sniper Attacks on IsraelHamas fires RPGs and sniper rounds at Israeli positions, ending any illusion of peace.03:30 – The Truth About the “Hudna” | Hamas' False Peace AgreementMonte explains the deceptive nature of the hudna — a false ceasefire allowing Hamas to rebuild for more war.05:15 – Israel's Mission: Disarm Hamas and Secure GazaDefense Minister Katz vows to eliminate Hamas completely to bring true peace to southern Israel.06:10 – Annexation of Judea and Samaria Passes First VoteThe Knesset narrowly approves annexation; one defiant Likud member swings the historic vote.08:00 – Trump's Peace Plan in Jeopardy | U.S. Pressure on IsraelVice President Vance and Secretary Rubio urge Netanyahu to pause annexation for regional stability.09:45 – Draft Dodgers and Torah Students Arrested | Israel's Internal DivideReligious exemptions spark national controversy as Haredi students face arrest for avoiding IDF service.12:00 – Religious Parties Lose Ground | Israelis Demand Equal ServiceThe Shas and United Torah Judaism parties face backlash as Israelis call for unity in defense.13:40 – Trump and Netanyahu Unite | Hostage Families Welcomed HomeMonte recaps Trump's visit to the Knesset and his joint efforts with Netanyahu to secure hostages' return.15:20 – U.S. Military Headquarters in Israel | CENTCOM Moves to Kiryat GatThe U.S. establishes a joint command center with Israel to oversee Gaza operations and enforce the ceasefire.17:00 – Is Israel Becoming a U.S. Protectorate? | Prophetic ImplicationsMonte explores concerns that Israel's sovereignty is being compromised — and what prophecy says about it.18:40 – King Charles Meets the Pope | A 500-Year Prophetic EventKing Charles and Pope Leo pray together in the Sistine Chapel for the first time in centuries.20:15 – Prophecy Watch: Could King Charles Be the Anti-Messiah?Monte examines biblical clues connecting the King-Pope alliance to end-time prophecy.22:10 – King Charles' Health Improves | Symbolism in the End TimesAfter a cancer diagnosis, King Charles' recovery and renewed public role draw global attention.23:00 – Pray for Israel | Stand Firm in Faith Amid Global ChaosMonte calls believers to prayer for Israel, the hostages, and all those affected by ongoing conflict.24:30 – Support Lion and Lamb Ministries | Shabbat Shalom from Monte JudahClosing remarks, ministry updates, and Monte's weekly Shabbat blessing.

Christian Balmer, an anesthesiologist and critical care doctor from Switzerland, joins us to look at the readiness of surgical teams in his organization to recognize and deal with cases that have gone beyond the capacity of the peripheral center to handle. Far from being a readiness plan around technical skills, the team discovers that it is the gray areas between intersecting teams and intersection institutions where the process of caring for the patient breaks down. Do the ICU teams at both hospitals agree about when is the right time to transfer the patient? Do the surgeons have training on stepping back and declaring that there is a crisis that needs to be managed via transport? Are there communication plans in place to make sure that the ICU has available beds, and to help the main hospital trust that when the peripheral group sends a patient, that patient has a real need for the ICU bed? Finally, we discuss aligning training programs from healthcare schools all the way to the hospital—if health systems are looking for teams that can talk to one another, work with patients, and provide care in a particular way, how can we make sure that the schools that are training future healthcare workers are in communication and prioritizing the skills and ability to learn that they will need to be ready for the job? -------------- Host & Co-Producer: Chris Roussin, PhD, Senior Director, CMS-ALPS (https://harvardmedsim.org/chris-roussin/) Producer: James Lipshaw, MFA, EdM, Assistant Director, Media (https://harvardmedsim.org/james-lipshaw/) Consulting and readiness with CMS-ALPS: https://harvardmedsim.org/alps-applied-learning-for-performance-and-safety Readiness Planning in Advances in Simulation: https://advancesinsimulation.biomedcentral.com/articles/10.1186/s41077-024-00317-z Dare to Be Ready on Spotify: https://open.spotify.com/show/72gzzWGegiXd9i2G6UJ0kP Dare to Be Ready on Apple Podcasts: https://podcasts.apple.com/us/podcast/the-center-for-medical-simulation/id1279266822

On this thicc episode of the Maximum Utcast, Jonathan interviews Matt Bozon and Michael Stragey of WayForward about their game Shantae Advance that originally began development over 20 years ago as a GBA game only to be shelved indefinitely before being revived this year. Shantae Advance finally got released this year on actual GBA cartridges through Limited Run Games or available digitally just about everywhere else. Jonathan also makes a plea for a sequel to Boogerman (which Michael produced and programmed). Later, Jonathan and Zoey talk about what a sequel to Boogerman might look like and we also reveal that this show has potentially always been an Earthworm Jim fan cast? Sometimes you gotta separate the art from the artist, and other time, you gotta hold the limes in your mind!0:00:00 - Comparing Cults0:07:47 - Holding the Limes of My Mind0:09:36 - The Magical Alchemy of Shantae Advance with Matt Bozon and Michael Stragey1:25:44 - Should They Make a Boogerman Advance?1:35:11 - The Subtle Distinctions of Earthworm Jim Versions1:37:08 - Separating Art from the Artist on this Earthworm Jim Fan Cast1:43:06 - Wrap Up/Plugs/Thanks Patrons!1:51:15 - Sweatshirt1:52:54 - That's the SpiritFollow WayForward on Bluesky: https://bsky.app/profile/wayforward.bsky.socialFollow Zoey on Bluesky: https://bsky.app/profile/adzuken.bsky.socialFollow Jonathan on Bluesky: https://bsky.app/profile/tronknotts.bsky.socialFollow the show on Bluesky: https://bsky.app/profile/ttwav.bsky.socialMaximum Utmost on website: https://maxutmost.com/Maximum Utmost's Ko-Fi: https://ko-fi.com/adzuken

 People increasingly seek personalized health care and wellness because they recognize that every individual's body, genetics, lifestyle, and emotional makeup are unique. Traditional one-size-fits-all approaches often fail to address these personal differences, leading to frustration and limited results. Personalized care tailors prevention, nutrition, exercise, and treatment plans to each person's specific needs and goals—improving effectiveness, satisfaction, and long-term health outcomes. Advances in genetics, wearable technology, and data-driven insights now make it possible to understand individuals more deeply than ever before, empowering people to take an active role in their well-being and fostering a sense of ownership, trust, and motivation in their health journey. Dr. Fred Clary, founder of Functional Analysis Chiropractic Technique and lifting/life coach/ gym-chalk covered philosopher talks about the demand for personalized Health and Wellness care! 

In this podcast, experts Tina Cascone, MD, PhD; Christina Baik, MD, MPH; and David Planchard, MD, PhD discuss data-driven treatment for EGFR-mutant non-small cell lung cancer.

This week's national park news roundup covers a wave of potential job cuts across the Department of the Interior — including hundreds from the National Park Service — plus new legislation in Congress aimed at tackling wildfires and forest management. We'll also look at wildlife making surprising moves in Yellowstone and Michigan, new state parks opening in Tennessee, major campground expansion plans in Michigan, and California's push to bring art and culture into its parks. Find the  Slinky Stove that's right for your next adventure at: https://www.slinkystove.com/?ref=PARKography Join the PARKography Facebook group to discuss this episode and more: https://www.facebook.com/groups/parkography

This week's national park news roundup covers a wave of potential job cuts across the Department of the Interior — including hundreds from the National Park Service — plus new legislation in Congress aimed at tackling wildfires and forest management. We'll also look at wildlife making surprising moves in Yellowstone and Michigan, new state parks opening in Tennessee, major campground expansion plans in Michigan, and California's push to bring art and culture into its parks. Find the  Slinky Stove that's right for your next adventure at: https://www.slinkystove.com/?ref=PARKography Join the PARKography Facebook group to discuss this episode and more: https://www.facebook.com/groups/parkography

(0:00) The second hour begins with discussing the Bruins 4-3 loss to the Panthers in Brad Marchand's return to Boston.(16:21) The callers weigh in on the Bruins and Celtics. (25:11) The guys discuss Bill Belichick and the NFL Hall of Fame. (34:03) More thoughts on the Robert Kraft and Bill Belichick Hall of Fame discussion.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Sex Differences in Cardiovascular Health Status and Long-Term Outcomes in a Primary Prevention Cohort.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Early Access to Tafamidis for Patients With Transthyretin Amyloid Cardiomyopathy.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Outcomes of Telemedicine TAVR Preoperative Evaluations.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Impact of Food Desert Residence on Ischemic Stroke and Hospitalization Risk in Atrial Fibrillation Patients.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Role of Artificial Intelligence in Reducing Data Deluge From Cardiac Implantable Electronic Devices.

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Total Atrial Conduction Time as a Predictor of Left Atrial Functional Recovery in Atrial Fibrillation.

After an hourslong meeting, the Hermantown City Council approved a needed zoning change to advance the proposed data center that's being developed by an unnamed Fortune 50 company. MPR News host Nina Moini spoke with MPR News correspondent Dan Kraker about the meeting that lasted late into the night.

Interview with Nicholas Bridgen, CEO of Ferro-Alloy Resources Ltd.Our previous interview: https://www.cruxinvestor.com/posts/ferro-alloy-resources-lsefar-low-cost-vanadium-play-preps-feasibility-study-for-june-2025-6715Recording date: 15th October 2025Ferro Alloy Resources has released feasibility study results for its Kazakhstan vanadium project, revealing exceptional economics that position the company among the lowest-cost producers globally. Phase 1 development demonstrates a net present value of $749 million with a 22% internal rate of return, while production costs of just $0.36 per pound after byproduct credits place the project in the bottom decile of global vanadium operations.Chief Executive Nicholas Bridgen attributes these compelling economics to two fundamental advantages. The company's sedimentary ore deposit differs markedly from the magnetite sources that supply 95% of global vanadium production, requiring no concentration or roasting processes. This geological advantage translates directly into lower processing costs and reduced environmental impact. Additionally, the deposit contains 8.5% carbon content that can be processed into carbon black substitute, a valuable byproduct for tire manufacturing commanding prices around $500 per ton.The project's strategic positioning extends beyond pure economics. With vanadium designated as a critical metal across Western countries, Ferro Alloy Resources benefits from multiple financing pathways as governments seek to diversify supply chains away from Chinese dominance. The carbon black substitute product carries approximately one-tenth the embedded emissions of conventional production, potentially adding $100-200 per ton in value as carbon tariffs expand globally.Phase 1 targets 8,500 tons of vanadium pentoxide annually, with Phase 2 conceptually three times larger. Seven ore bodies have been identified across the project area, though only the first has been fully incorporated into current planning. Existing infrastructure including power lines, road access to international rail connections, and favorable open-pit mining conditions reduce both capital requirements and execution risk.The company now advances toward front-end engineering design, evaluating both Western financing aligned with critical minerals strategies and competitive Chinese contractors for cost-efficient development. With a 15,000 ton-per-year pilot plant already demonstrating superior recovery rates compared to laboratory testing, Ferro Alloy Resources presents investors with a de-risked pathway into vanadium production at a strategically significant moment for global supply chains.View Ferro-Alloy Resources' company profile: https://www.cruxinvestor.com/companies/ferro-alloy-resourcesSign up for Crux Investor: https://cruxinvestor.com

Cardiovascular care is entering one of its most transformative periods in decades. Advances in AI imaging and minimally invasive procedures are transforming the diagnosis and treatment of heart disease. According to the World Health Organization, an estimated 19.8 million people died from cardiovascular diseases in 2022, representing approximately 32% of all global deaths. This makes early detection, innovation, and prevention critical. New technologies promise faster procedures and better outcomes. However, the challenge is to ensure that access, affordability, and quality keep pace with innovation.As technology redefines what's possible in cardiovascular medicine, how can health systems balance innovation with sustainability and make excellence more than just a marketing term?In this episode of I Don't Care, host Dr. Kevin Stevenson reconnects with longtime colleague Jorge Parodi, a cardiovascular service-line leader with experience across major hospitals and health systems. Together, they trace the evolution of cardiovascular care from the rise of service-line models to the latest AI-driven tools shaping diagnosis and treatment. They also unpack what “centers of excellence” really mean today.Key Points of Conversation:From Service Lines to Systems Thinking: How hospitals began aligning cardiovascular services around the patient journey and cutting across departments to improve coordination, quality, and outcomes.Technology at the Heart of Care: Advances like pulse field ablation, AI-assisted CT imaging, and next-generation diagnostic tools are revolutionizing early detection and treatment while reducing invasiveness.Redefining Excellence: Why “center of excellence” designations vary widely across payers and regulators, and how data-driven quality metrics are reshaping what true cardiac leadership looks like.Jorge Parodi is a senior healthcare executive with over two decades of leadership in cardiovascular service line management and hospital operations. He has directed major heart and vascular programs across leading health systems, focusing on strategy, innovation, and quality improvement. Parodi specializes in developing high-performing, technology-driven cardiovascular programs that enhance patient outcomes and operational efficiency.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Recent developments in these industries underscore a period of significant scientific progress, regulatory maneuvers, and strategic investments.One notable event was AstraZeneca and Daiichi Sankyo's success at the European Society for Medical Oncology Congress 2025. Their antibody-drug conjugate, Datroway, demonstrated superior efficacy compared to Gilead's Trodelvy in the first global head-to-head trial involving Trop2-targeted therapies. This reflects the increasing focus on antibody-drug conjugates as precision medicine tools that offer targeted treatment options with potentially improved outcomes over traditional chemotherapy.In a move highlighting the ongoing trend of bolstering domestic production capacities, Merck is making a substantial $3 billion investment in a small molecule drug plant in Virginia. This is part of a broader $70 billion commitment to expand manufacturing and R&D capabilities in the U.S. Such strategic investments are crucial for maintaining competitive advantage and ensuring drug availability while meeting rising demands and streamlining supply chains.Turning to regulatory updates, the FDA has approved Amgen and AstraZeneca's Tezspire for chronic rhinosinusitis with nasal polyps. This marks Tezspire's second indication, following its initial approval for severe asthma in 2021. The expanded approval showcases the drug's versatility and represents a strategic push to enhance its market presence against competitors like Dupixent.In oncology, Merck's Keytruda and Astellas/Pfizer's Padcev have made headlines with compelling results in muscle-invasive bladder cancer. The combination therapy reduced the risk of death by 50%, reinforcing Keytruda's position as a cornerstone immunotherapy across multiple cancer types. This result not only augments treatment options but also signifies the potential for combination regimens to enhance patient outcomes.Roche has expanded the indication of its aging oncology drug Gazyva to treat lupus nephritis, demonstrating strategic repurposing efforts to extend the lifecycle of existing therapies. While this expansion into autoimmune diseases comes late in Gazyva's lifecycle, it highlights a growing trend of capitalizing on established drugs for new therapeutic areas.AstraZeneca and Daiichi Sankyo's Enhertu showed robust efficacy in early breast cancer treatment, potentially reshaping therapeutic strategies by offering new hope for early intervention. Similarly, Novartis' Pluvicto demonstrated promise in slowing hormone-sensitive prostate cancer progression, underscoring the potential of radioligand therapies in oncology.However, not all developments have been positive. AstraZeneca faced setbacks when its Imfinzi and Lynparza combination failed to meet survival goals in ovarian cancer, underscoring the challenges inherent in oncology drug development and the stringent benchmarks set by regulatory authorities like the FDA.The industry is also witnessing significant advancements in next-generation ADCs, as evidenced by Tubulis' 59% response rate in early clinical trials, which has attracted substantial investor interest. Additionally, Grail's Galleri cancer blood test is progressing towards FDA review with enhanced performance data, potentially revolutionizing cancer screening and early detection practices.These scientific and regulatory milestones are complemented by strategic investments in bioconjugation technologies. Cohance Life Sciences' $10 million investment in NJ Bio to enhance GMP bioconjugation capabilities exemplifies this trend. Such investments are crucial for advancing ADC development, which remains a focal point for innovative cancer therapies.Overall, these developments reflect a dynamic phase for the pharmaceutical and biotech sectors characterized by signSupport the show

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Development of an Electronic Medical Record–Based Score for Heart Failure Prediction in Cancer Survivors.

On this episode, I'm joined by Dr. Karli Provost Goldstein, a renowned expert in endometriosis and minimally invasive gynecology. Together, we dive into the challenges of diagnosing and treating endometriosis, a condition that is often misunderstood and underdiagnosed. Dr. Goldstein shares her expertise on why endometriosis frequently goes undiagnosed for years, the differences between surgical approaches like robotic and laparoscopic surgery, and the connection between endometriosis and infertility. Here's what we cover in this episode: The complexities of diagnosing endometriosis and why it's often delayed Advances in minimally invasive gynecology for treating endometriosis The critical role of fertility preservation for patients with endometriosis A comparison of robotic and laparoscopic surgical techniques The link between endometriosis and ovarian cancer Read the full show notes on Dr. Aimee's website. Resources: Dr. Karli Provost Goldstein's website: Esse Care Dr. Karli Provost Goldstein on Instagram Get Dr. Aimee's Fertility Essentials Do you have questions about IVF?Click here to join Dr. Aimee for The IVF Class. The next live class call is on Monday, October 20th, 2025 at 4pm PST (7pm EST), where Dr. Aimee will explain IVF and there will be time to ask her your questions live on Zoom. Dr. Aimee Eyvazzadeh is one of America's most well known fertility doctors. Her success rate at baby-making is what gives future parents hope when all hope is lost. She pioneered the TUSHY Method and BALLS Method to decrease your time to pregnancy. Learn more about the TUSHY Method and find a wealth of fertility resources at www.draimee.org.

Valkea Resources' Chris Donaldson updated Mining Stock Daily on the opportunity he sees in Finland and the company's current drilling campaign. Valkea Resources (TSX-V:OZ) is focused on the Central Lapland Greenstone Belt. The company's flagship asset is the Paana project."It's exciting times, and putting out gold results in this gold environment is a nice thing to do," said Donaldson, noting high metal prices.

This week, I sit down with two incredible guests to unpack one of the most talked-about (and misunderstood) press conferences in recent months. I'm joined by Dr. Tanya Altmann, pediatrician and founder of Calabasas Pediatrics Wellness Center, and Dr. Anshu Batra, developmental-behavioral pediatrician and autism specialist, to separate fact from fear when it comes to Tylenol, leucovorin, and autism. We talk about what the latest research actually shows, what parents should know, and why conversations about autism deserve more nuance and empathy than political headlines. We discuss: What current research tells us about autism's causes, including the strong role of genetics and the complex mix of environmental and developmental factors. Why studies on Tylenol and autism don't prove causation, and how correlation has been misunderstood in headlines and online discussions. How leucovorin (folinic acid) may support some children with autism, why it's not a cure, and what doctors are actually seeing in practice. The connection between micronutrients, gut health, and neurodevelopment, plus real barriers families face in getting lab work and supplements covered. What early screen exposure can do to developing brains, and why less screen time and more real-world interaction matter for young children. Where research and funding need to go next, from identifying subtypes of autism to improving access to early intervention and therapeutic schools. To connect with Dr. Tanya Altmann check out all her resources at Drtanya.com.  Follow her on Instagram at @drtanyaaltmann. 00:00 Introduction 02:05 Meet the Guests 04:09 The Tylenol Controversy 06:41 What We Know About Autism Causes 09:02 Advances in Autism Research 14:15 The Role of Genetics and Environment 18:15 What Is Leucovorin 22:25 What Parents Are Seeing 27:10 Who Might Benefit 29:20 Micronutrients, Gut Health, and Screen Time 38:28 What Research Still Needs to Happen 45:54 Reactions to the White House Press Conference 52:41 Final Takeaways for Parents and Clinicians 55:29 Outro and Reflection We'd like to know who is listening! Please fill out our Listener Survey to help us improve the show and learn about you! Our podcasts are also now on YouTube. If you prefer a video podcast with closed captioning, check us out there and ⁠subscribe to PedsDocTalk⁠. Get trusted pediatric advice, relatable parenting insights, and evidence-based tips delivered straight to your inbox—join thousands of parents who rely on the PDT newsletter to stay informed, supported, and confident. ⁠⁠⁠⁠Join the newsletter⁠⁠⁠⁠! And don't forget to follow ⁠⁠⁠⁠@pedsdoctalkpodcast⁠⁠⁠⁠ on Instagram—our new space just for parents looking for real talk and real support. We love the sponsors that make this show possible! You can always find all the special deals and codes for all our current sponsors on the ⁠PedsDocTalk Podcast Sponsorships⁠ page of the website.  Learn more about your ad choices. Visit podcastchoices.com/adchoices

Join us for the October edition of the Simulcast Journal Club, hosted by Vic Brazil and Ben Symon. In this episode: AI in simulation, simulation reducing sick leave, calculating the cost of simulation, and simulation based toolkits to address hospital acquired conditions.     The October papers   Cheng A, McGregor C. Applications of artificial intelligence in healthcare simulation: a model of thinking. Advances in Simulation. 2025;10:45. https://doi.org/10.1186/s41077-025-00379-7   Schram AL, Bonne NL, Henriksen TB, Hertel NT, Petersen PG, Bjerrum MC, et al. Effect of simulation-based team training on sick leave among healthcare professionals: a multisite controlled follow-up study. Journal of Healthcare Simulation. 2025 Sep 3. https://doi.org/10.54531/XCVT3140   Verhoeff TL, Janssen JJHM, Röell AE, Hoff RG. The surprising costs of on-site surgical team CRM training: a Dutch example analyzed. Advances in Simulation. 2025;10:37. https://doi.org/10.1186/s41077-025-00367-x   Barker LT, Bond WF, Willemsen-Dunlap AM, Cooley KL, McGarvey JS, Ruger RL, et al. Simulation-Debriefing Enhanced Needs Assessment to address quality markers in health care: an innovation for prospective hazard analysis. The Joint Commission Journal on Quality and Patient Safety. 2025;51:144–158. https://doi.org/10.1016/j.jcjq.2024.10.004     Another great month on Simulcast.  Happy listening 

Facioscapulohumeral muscular dystrophy (FSHD) is one of the most common forms of muscular dystrophy, affecting individuals across the lifespan with variable severity. Advances in genetic understanding and therapeutic development have led to an era of promising disease-modifying strategies. In this episode, Katie Grouse, MD FAAN, speaks with Renatta N. Knox, MD, PhD, author of the article “Facioscapulohumeral Muscular Dystrophy” in the Continuum® October 2025 Muscle and Neuromuscular Junction Disorders issue. Dr. Grouse is a Continuum® Audio interviewer and a clinical assistant professor at the University of California San Francisco in San Francisco, California. Dr. Knox is an assistant professor of neurology in the Division of Pediatric Neurology and Neuromuscular Section at Washington University School of Medicine in St. Louis, Missouri. Additional Resources Read the article: Facioscapulohumeral Muscular Dystrophy Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN  Full episode transcript available here Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast. Dr Grouse: This is Dr Katie Grouse. Today I'm interviewing Dr Renatta Knox about her article on fascioscapulohumeral muscular dystrophy, which appears in the October 2025 Continuum issue on muscle and neuromuscular junction disorders. Welcome to the podcast, and please introduce yourself to our audience. Dr Knox: Hi Katie, thank you so much for the invitation for the audio interview. I'm looking forward to our conversation. As she mentioned, my name is Renata Knox. It's a pleasure to be here today. Dr Grouse: I'd like to start by asking, what is the key message that you hope your readers will take from your article? Dr Knox: I would say two things. The first is an appreciation and understanding of the unique genetic mechanism that leads to FSHD. And the second is the really exciting therapy landscape that we find ourselves in. So, we're hopeful that there will actually be disease-modifying therapies for FSHD soon. Dr Grouse: We're really looking forward to learning more about that. Now, before we get to that piece, could you just remind us of the clinical manifestations and features that are specific to FSHD? Dr Knox: So, one of the most unique things about FSHD that we see clinically is the pattern of weakness. So, one of the first features is that it's asymmetric. And then there are certain muscle groups that typically are affected, and that's partly where the name comes from. So, we see effects in the face, the limbs, the trunk; and so, those are some of the unique features that we see clinically. Dr Grouse: I'd love it if you could walk us through how you approach diagnosing a patient who presents with proximal weakness where FSHD is in your differential. Dr Knox: Yeah, it's a really great question. So, I would say it depends. So, I actually focus on FSHD in my clinical practice. So, many times patients are referred to me because there's a very high suspicion or there's a known family history of FSHD. So, that's one category of cases. I would say the other category of case is where it's, as you said, maybe more proximal weakness more broadly. Someone that's before me who has a known family history, they really have some of the characteristic physical features---which I'm pretty attuned to, as this is, you know, part of my subspecialty---I'll actually go directly to FSHD genetic testing. And that is one of the unique features of this disease, that the next-generation sequencing panels that are typically used for some of our other muscle diseases, FSHD is not captured on those. So, we actually have to send targeted testing for FSHD to diagnose it. So, that is one category where, again, I have a very high suspicion either based on their clinical presentation and/or a known family history, then I will actually go directly to FSHD-targeted genetic testing. In the second case, where it is one of the conditions that I'm considering among others, I will do more broad testing. So, I will get a CK level to see if there's evidence of muscle breakdown. I'll likely also do one of the next-generation sequencing panels that we have access to, which will allow us to identify, potentially, one to two hundred potential muscle diseases. And then again, if FSHD is higher on my differential in that second group of patients, then I will also send targeted FSHD-specific testing. Dr Grouse: That's really helpful. And I'm wondering if you have any thoughts about common pitfalls that you've seen when providers are trying to work this up? Dr Knox: I don't know if I would say pitfalls. I think I would acknowledge that it's challenging. My subspecialty training in neuromuscular medicine and also gene therapy. And so FSHD is pretty high on my radar. But I would say in neurology in general---and then, you know, the general medical population---,it really isn't something that many people are seeing. So, I would say what patients will communicate to us sometimes is some frustration that maybe it took time to make the diagnosis, but I just have a deep understanding that it's not something that is on many people's radars. And I think, again, it's tricky because it's not picked up on these next-generation sequencing panels, which many of us can send pretty easily. It will be missed. And I will say the biggest pitfall is, again, if you're not thinking about it and you don't send that testing, you actually- it's very difficult to diagnose it. Dr Grouse: Thank you so much for highlighting that. I think there are many people who are not aware that those different panels really aren't picking that up and that they have to test specifically. So, I think that's a great thing for all of us to keep in mind. Are there any tips or tricks to the diagnosis, other than the genetic issues that you mentioned, that sometimes can really bring this diagnosis to the forefront? Dr Knox: I think things that really tip me off to having a higher suspicion for FSHD is facial weakness that we can detect on our exam. Scapular winging---again, there's a small subset of disorders which can impact that. Someone who's presenting with foot drop, you know, with facial weakness, I think definitely about FSHD more. Also, clinically, kind of the presentation or things that they're beginning to have difficulty with is a tip-off. So, if someone is an athlete, like, they're a volleyball player or basketball player and they say, oh, I'm having difficulties, you know, with movements that require them to elevate their arm, which can be a sign of the shoulder weakness that we classically see. Or someone who says, oh, I'm having a harder time shampooing my hair or combing my hair. So those can be tip-offs again, which are basically referencing the type of weakness that they have. Another feature of FSHD which isn't necessarily as broadly appreciated is that pain and fatigue are very common. So, if someone is coming in and saying, actually, I also have a significant amount of fatigue as well or a lot of pain, that's something that can tip me off to it. Hearing loss is something that we can also see in up to 20% of patients with FSHD. So, if they are having those symptoms or saying they're ringing in their ears, these are some things that will make me begin to think about it more. Dr Grouse: Oh, really helpful. I also found it really fascinating reading some of the very FSHD-specific clinical signs, some interesting- some diagrams and pictures as well, that are very specific to the pattern of weakness that develops in FSHD. So, I encourage our listeners to check that out. But are there any highlights from those little clinical pearls that you'd like to point out? Dr Knox: I think the poly-hill sign---so, these are these literal hills that we can see in the shoulders of patients with FSHD---is pretty classic. Popeye arms, which is this older term that we still use that has to do with which muscle groups are preserved versus those that have atrophy. So that's a common feature. And then I would say, really, the asymmetry is something that is a unique feature in FSHD. And again, we did our best to provide good representative images. So again, as you mentioned, Katie, I would really encourage people to look at those images and then think about cases that they may have seen and how similar they are so they can begin to recognize those signs as well. Dr Grouse: Now going back to the genetic topic, the complex genetic underpinnings of FSHD are really well-explained in your article; and again, worth taking a look at to remind ourselves of everything that's of that pathology. Now, I was wondering though, if you could give us a brief overview of how we should approach genetic testing in a suspected case of FSHD? You mentioned some specific panels, but it does sound like there's some more complexity to it as well. Dr Knox: Yes, and I'll just kind of briefly explain that complexity. Part of the thing that we're detecting in the genetic testing is the repeat number. And so, we're actually looking for a contraction in a repeat number. So, not an expansion, which were typical for some of the diseases that we think about, the trinucleotide repeat disorders. And this is why it's not captured in the next-generation sequencing panels, because they do not currently have the ability to do that. And so, again, what the type of testing that I do really depends on my suspicion. So again, if my suspicion is very high for FSHD---they have a family history, they have the classic features---then I will actually go directly to an FSHD-specific testing, which is available from various sources. If, again, it's among different things that I'm thinking about, I will get a CK lab. I typically will also send a next-generation sequencing panel specific for muscle diseases, perhaps muscular dystrophy; again, depending on what I'm thinking about. And then I will also send in a specific FSHD genetic test as well. People are beginning to use whole-genome sequencing, which is capturing some of our true nucleotide repeat disorders and becoming more comprehensive. So, my hope is that as that becomes more standard of care---like, whole-exome sequencing can be gotten pretty routinely now---that it may be easier for us to make some of these diagnoses. Dr Grouse: Well, that's really helpful, and thanks for that overview. Now another thing that you mentioned that I thought was really interesting in your article was that patients with, you know, history of FSHD, perhaps in the family, who are pregnant and want to screen for this disease would not be able to use sort of the more common screening tests like cell-free DNA testing and may have to go to other means to do that. What is generally their route to this type of testing? Dr Knox: Yeah, great question, and really important question for family planning purposes, and it definitely comes up in clinical practice. And so again, because of the unique genetics of FSHD, you actually have to do invasive genetic testing currently to be able to test it. And so that's, you know, amnio or chorio, and then send it to a lab that can perform, again, FSHD-specific testing on the samples that are presented. And there are obviously labs that are capable of doing that and centers that are capable of doing that, but it is not picked up on the cell-free DNA panels that are being very routinely used. You or your provider has to be thinking about it to send that specific testing, similar to our patients that come into clinic and have not yet been diagnosed. Dr Grouse: Once you have the diagnosis, what are our options for therapy? I think it sounds like at this current time, it looks to be mostly supportive. What are some of the supportive care options we should keep in mind? Dr Knox: Yes, so that is definitely accurate. Care today is supportive, but again, we're very excited about the clinical trial and therapy landscape for FSHD. So, I work very closely with my physical therapy colleagues that are in clinic with me. So, we work very closely with physical and occupational therapists to help with supportive measures, adaptive measures, doing assessments, helping our patients to be able to move and exercise safely and effectively. As I mentioned, pain is very common in FSHD and so we can treat that with medications. The most common medication that we use to treat for pain in FSHD are NSAIDs. And then other than that it's really, you know, supportive measures. Do they need to see other subspecialists? There are some surgical options. Those are used very rarely to help with some of the scapular weakness, but typically it's physical therapy, occupational therapy, supportive devices. We treat the pain as we're able to, and then we work with other subspecialists to screen, monitor and support our patients to the best of our ability. Dr Grouse: Well, without further ado, I'd love to hear more about what's coming down the pipeline in clinical trials. What can we look forward to seeing, hopefully, in future years to treat these patients? Dr Knox: Yes. And so, this is actually what got me interested in the neuromuscle space in general is that, because we now for many years have known the genetic cause of many of these disorders as well as some of the underlying mechanisms, we can actually use advances in therapeutics to do what we call targeted therapies. So, rather than treating symptoms or indirect methods or doing kind of broad drug screens---which, again, still do take place and still do have their place---we actually can target mechanisms directly. And so, we know that the underlying biology of FSHD is due to this protein called DUX4 being expressed when it should not be. So, it's what we call a toxic gain of function. And so, the targeted way to address this is to suppress DUX4 expression. And so, kind of broadly speaking, what we're really excited about are a couple of products that are currently in clinical trials right now that actually caused DUX4 suppression to be suppressed. And again, these are targeted pathways. And so, again, the hope is that by doing that, we can hopefully slow the progression of the disease, potentially stop progression of the disease, and potentially reverse. Again, we don't know if that might be possible, but that is one of the hopes. Dr Grouse: Well, that's really exciting, and I know we're all looking forward to more coming down the pipeline soon, and hopefully more things that can really offer some exciting treatments for our patients with this condition. Now, a little more deep-dive into our patients who are diagnosed. You've reviewed some of the treatments currently available and hopefully may someday soon be available. Are there other things that we should be keeping in mind in this population? For instance, screenings that we should be doing for other extramuscular manifestations that we need to be thinking about? Dr Knox: I will answer that question two ways. I think something that's very important to acknowledge is the impact that these diagnoses and these conditions have on our patient practically, psychologically. One of the other unique features of FSHD is, it's autosomal-dominant. So, if it is in a family, you can have many family members who are affected, but the variability is very high. And so, you can have in the same family someone who is wheelchair-dependent, and someone else in the family with the same underlying genetics who has no signs or symptoms or is very mildly affected. And that is something that is definitely challenging for our families and patients to navigate if they're very different than their family members with the same condition. And just navigating the world with a condition that, you know, can be physically debilitating and cause changes to what they're able to do or not able to do, progression is something that's very difficult to handle. So, I think that's one set of things. And we try our best, you know, with my team and my other colleagues in the space, to support our families and patients in the best way that we can. Secondly, there is very important screening that needs to be done for this condition. So, one of the things- and the current guidelines which are actually being updated, the last update was in 2015 is all patients that undergo pulmonary function testing or PFTs. And so that's something we do at baseline and we do at least annually in my practice. Young kids who are presenting very early or patients with certain genetics that we know are more predisposed to extra muscular manifestations, we recommend screening for hearing, which is one of the manifestations, and ophthalmologic exam to look for retinovascular changes, which is one of the manifestations as well. Those are the more common ones that are typically done. There's also some evidence in pediatric patients with very severe manifestations that there may be some cognitive impacts, learning impacts. And so, that is something we're also thinking about screening and supporting our patients in that way. And again, we typically work with these patients in a multidisciplinary team depending on what manifestations and the degrees to which they're impacted by the disorder. Dr Grouse: Thank you so much for that answer. I think a lot of us forget sometimes when we get really focused on what can we do now, that we forget to kind of stop and reflect on sort of the more holistic approach. How is this affecting the patient? How is this affecting the patient's family dynamic, and what other ways are they going through life with this condition that we need to be thinking about? So, I appreciate you bringing that up. I wanted to ask, sort of based on what you're talking about and what you mentioned already, you happened to mention that what initially drew you that to this work was your interest in some of the really exciting breakthroughs in the field. Well, was there anything else that drew you to, specifically, congenital neuromuscular diseases, and FSHD in particular? Dr Knox: I'm a physician scientist by training, and so I would describe myself also as a molecular biologist. So, I love getting into the nitty gritties of disease mechanisms, what genes are doing in bodies, how they function. And so, as I mentioned earlier, in the neuromuscle space, we've known for many years the genetic cause of many of these disorders and have done great, you know, mechanistic work to kind of define why we see the disease. And then now we're at this intersection of that knowledge marrying with these really novel therapeutic approaches, gene therapy approaches, being able to intersect and then in very creative ways actually target diseases very directly. And so, I would say it really is the combination of those two things. FSHD has a really fascinating unique biology, which again, we encourage everyone to read about more in the article. That really drew me to it. I'm very interested in gene regulation, transcription. This is one of the underlying mechanisms that is gone awry in the disorder, and then that being married to advances in therapeutics. So, you could wed those two pieces of information and actually meaningfully impact patient 's lives. And again, that's the real privilege and honor to witness is how these therapies can transform lives. And I saw it happened with this one case for this one disorder when I was a resident where there was no treatment. Young children, unfortunately, would not survive the disease. And then I saw the therapy come be in development and literally change the trajectory. And this is what we're very hopeful for in the FSHD space, that wedding, this wonderful basic science research, translational research, companies working together to develop these therapies that can transform lives. It is just so beautiful to witness and see, and it's something that I get to do. You know, it's a part of my job, so it's a real privilege. Dr Grouse: Well, I have to say, it's really inspiring hearing you talk about it. And I imagine that many neurologists-in-training who are listening to this may be inspired as well and may be convinced to go into this field for that very reason. So, thank you so much for sharing all of this information with us today. I learned a lot, and I think all of our listeners have too. Dr Knox: Thank you. It's really been a pleasure. Dr Grouse: Again, today I've been interviewing Dr Renatta Knox about her article on fascioscapulohumeral muscular dystrophy, which appears in the October 2025 Continuum issue on muscle and neuromuscular junction disorders. Be sure to check out Continuum Audio episodes from this and other issues. And thank you to our listeners for joining today. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

Samantha Croston and Ashley Wenskoski are back and October baseball is in full swing! Predicting how the NLCS and ALCS will shake out - which outcomes are better for the game of baseball? Can the Dodgers repeat? PLUS, a discussion on an MLB salary cap and rumors about what kind of contract Pete Alonso is looking for. 00:00-12:48: Are the Brewers are BAD matchup for the Dodgers? NLCS prediction 12:49-20:54: Are the Blue Jays in TROUBLE? ALCS prediction 20:55-27:11: Could the Dodgers/Brewers series impact a possible MLB SALARY CAP? 27:12-32:24: Pete Alonso is rumored to be looking for a 7-year deal....should the Mets give it to him? #mlb #mlbb #mlbbaseball #baseball #podcast #mlbpodcast #mlbplayoffs #nlcs #alcs #playoffs #losangeles #losangelesdodgers #dodgers #dodgersbaseball #milwaukee #milwaukeebrewers #brewers #bluejays #torontobluejays #newyorkmets #mets #petealonso #newyork #mariners #seattle #seattlemariners #mlbbcreatorcamp LIKE, COMMENT, SUBSCRIBE, LISTEN ON ALL PLATFORMS: https://www.flowcode.com/page/whymetspod Learn more about your ad choices. Visit megaphone.fm/adchoices

Our coverage of Anesthesiology 2025 begins, presented by Desiree Chappell and Andy Cumpstey with their guest Annery Garcia-Marcinkiewicz MD MSCE, Care Medicine at the Children's Hospital of Philadelphia, University of Pennsylvania. The discussion highlights the unique challenges and anatomical differences in pediatric patients, elaborates on the evolution of airway management tools and the impact of the Pediatric Difficult Intubation Registry. We underscore the benefits of video laryngoscopy over direct laryngoscopy in improving first-attempt success rates and reducing complications, especially in small, vulnerable infants. The episode concludes with practical advice for clinicians and the importance of advanced equipment in enhancing patient safety and efficiency in pediatric anesthesiology. https://www.pediregistry.org/